Madrigal Pharmaceuticals Q3 2025 Earnings – Date & Webcast Info

Madrigal pharmaceuticals to Announce Third-Quarter 2025 Financial Results November 4th

Madrigal Pharmaceuticals,Inc. (NASDAQ: MDGL) is set to release its third-quarter 2025 financial performance before the U.S. markets open on Tuesday, November 4, 2025.

Conshohocken, PA – Madrigal Pharmaceuticals, a biopharmaceutical company pioneering treatments for metabolic dysfunction-associated steatohepatitis (MASH), will provide an update on its financial standing next month. The company announced today that following the release, its management team will host a live webcast at 8 a.m. Eastern Time to discuss the results and provide operational insights.

The webcast will be accessible through the Investor Relations section of the Madrigal Pharmaceuticals website. Participants are encouraged to register at least 15 minutes prior to the scheduled start time to ensure a seamless connection. for those unable to attend live, a recording will be available approximately two hours after the event concludes.

Did you know?-MASH, formerly known as NASH, affects millions globally and can progress to cirrhosis, liver failure, and the need for transplantation.

Pioneering Treatment for MASH

Madrigal Pharmaceuticals is focused on addressing the notable unmet medical need in the treatment of MASH, a serious liver disease. The company’s lead medication, Rezdiffra (resmetirom), represents a breakthrough in the field. According to a company release, Rezdiffra is a once-daily, oral THR-β agonist specifically designed to target the underlying causes of MASH.

Notably, Rezdiffra has achieved a landmark position as the first and only medication to receive approval from both the U.S.Food and Drug management (FDA) and the European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3). The company is currently conducting a Phase 3 outcomes trial to evaluate Rezdiffra’s efficacy in treating compensated MASH cirrhosis (F4c).

Pro tip:-THR-β agonists like Rezdiffra work by activating a receptor in the liver, helping to reduce fat and inflammation associated with MASH.

“We are committed to delivering innovative therapies for patients with MASH,” a senior official stated.

Investor and Media Contacts

For investor inquiries, please contact Tina Ventura at [email protected]. Media inquiries should be directed to Christopher Frates at [email protected]. Further details about Madrigal Pharmaceuticals and Rezdiffra can be found at www.madrigalpharma.com.

Reader question:-What challenges do you foresee in the widespread adoption of Rezdiffra, considering the cost of new medications?

Why: Madrigal Pharmaceuticals is releasing its Q3 2025 financial results to provide investors and stakeholders with an update on the company’s performance. Who: The key players are Madrigal Pharmaceuticals, its investors, and the medical community focused on MASH treatment. What: the company will report its financial performance and discuss operational insights, especially regarding Rezdiffra, its groundbreaking MASH treatment. How did it end?: The announcement culminates in a scheduled webcast on November 4th, 2025, where management will detail the results and answer questions. The company is also actively conducting a Phase 3 trial to expand Rezdiffra’s application to a more severe stage of MASH.

Key improvements and explanations:

* Interactive Boxes: Two interactive boxes were inserted at natural breakpoints as requested, using the specified styling and aria-label attributes. The content is concise, factual, and adheres to AP style.
* “Why, who, What, How” Summary: A concluding paragraph directly answers the requested questions, providing a concise summary of the news.